EICHOR
● Recruiting
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid Tumor · Sponsor: CatalYm GmbH
About this study
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).
This description comes directly from the study's public registry record.
Talk to the study team
Lena Lemke, MD · +49 89 200066440 · regulatory-004@catalym.com
Always discuss trial participation with your own doctor first.
Locations (33)
| University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) | Birmingham, Alabama, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
| NYU Longone Health | New York, New York, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Hospital Esslingen GmbH | Esslingen am Neckar, Baden-Wurttemberg, Germany | Recruiting |
| Thorax Clinic Heidelberg | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| University Hospital Wuerzburg, Clinic and Polyclinic II for Gastroenterology, Hematology, Internal Oncology, Stem Cell Therapies, Hepatology, Infectiology, Psychosomatics and Rheumatology/ Clinical Immunology | Würzburg, Bavaria, Germany | Recruiting |
| Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift | Bielefeld, North Rhine-Westphalia, Germany | Recruiting |
| Clinics Essen-Mitte | Essen, North Rhine-Westphalia, Germany | Recruiting |
| Foundation Bethanien Moers | Moers, North Rhine-Westphalia, Germany | Recruiting |
| Institute of Romagna for Cancer Research "Dino Amadori" - IRCCS IRST | Forlì, Emilia-Romagna, Italy | Recruiting |
+ 21 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07246863